# Study to Evaluate Safety, Dose Response and Immunogenicity of the Measles Vaccine MVA mBN85B in Healthy Children Aged 6 Months to 6 Years

> **NCT00891007** · PHASE2 · COMPLETED · sponsor: **Bavarian Nordic** · enrollment: 90 (actual)

## Conditions studied

- Measles

## Interventions

- **BIOLOGICAL:** MVA-mBN85B
- **BIOLOGICAL:** MVA-mBN85B
- **BIOLOGICAL:** Rouvax

## Key facts

- **NCT ID:** NCT00891007
- **Lead sponsor:** Bavarian Nordic
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06
- **Primary completion:** 2010-07
- **Final completion:** 2010-08
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2012-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00891007

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00891007, "Study to Evaluate Safety, Dose Response and Immunogenicity of the Measles Vaccine MVA mBN85B in Healthy Children Aged 6 Months to 6 Years". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT00891007. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*